Citi has assigned a ”Buy” rating to Michael Saylor’s struggling Bitcoin treasury firm Strategy, forecasting 61% upside over the next 12 months based on Bitcoin [...]Citi has assigned a ”Buy” rating to Michael Saylor’s struggling Bitcoin treasury firm Strategy, forecasting 61% upside over the next 12 months based on Bitcoin [...]

Citi Says ‘Buy’ Michael Saylor’s Struggling Strategy, Sees 61% Upside On $181K Bitcoin Target

Citi has assigned a ”Buy” rating to Michael Saylor’s struggling Bitcoin treasury firm Strategy, forecasting 61% upside over the next 12 months based on Bitcoin hitting the bank’s $181,000 price target.

Strategy is a ‘’leveraged proxy’’ for Bitcoin’s performance, the Wall Street investment bank said in an Oct. 21 research note. It set a $485 price target for Strategy shares, assuming Bitcoin hits its 12-month price forecast and the company maintains its typical premium to net asset value.

But its analysts warned that while the stock offers outsized upside in bull markets, it also magnifies downside losses. A 25% pullback in BTC, they warned, could swing Strategy’s NAV from a 35% premium to a discount and cut the stock’s value by as much as 61%.

“The stock presents significant risks due to its positioning as a leveraged proxy for Bitcoin,” Citi analysts said. ”Its value is nearly 100% tied to the sometimes-volatile cryptocurrency, meaning that even a moderate decline in Bitcoin’s price can lead to magnified losses for MSTR shareholders.”  

Crypto Treasury Firms Face Turbulent Times

Citi’s buy recommendation comes at a tough time for Strategy, which has seen its share price slump 10% in the past month, magnifying Bitcoin’s 4% loss over the same period.

MSTR rose more than 1% yesterday but is down more than 2% in pre-market trading. 

Other crypto treasury firms are also under pressure, squeezing their ability to raise funds for more purchases. 

Japan-based Metaplanet has seen its stock price fall over 27% in the past month, prompting CEO Simon Gerovich to announce that the firm has paused its share issuance as part of an effort to optimize the company’s fundraising strategy

BitMine Immersion Technologies, the largest Ethereum treasury firm, has plunge 5% in the past month, while fellow ETH-focussed firm SharpLink Gaming has slumped more than 13%. 

Strategy Keeps On Buying

Strategy started accumulating Bitcoin back in 2020 and has become the largest corporate Bitcoin holder globally. According to data from Bitcoin Treasuries, Strategy holds 640,418 BTC on its balance sheet. 

Top 10 corporate BTC holders (Source: Bitcoin Treasuries)

That’s over 12 times more than the second-biggest Bitcoin treasury firm, MARA Holdings, with its reserves of 53,250 BTC.

And it shows no signs of stopping its BTC accumulation after announcing another purchase of 168 BTC for $18.8 million on Monday.

The average purchase price was about $112,051 per BTC, Saylor said. It cost the company around $47.4 billion to acquire all of its holdings, with the overall mean price for the purchase at $74,010 BTC, Saylor added. 

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26